Necrosis cutánea por interferón alfa en paciente con melanoma

García, Guadalupe Aguilar; Falcón, Cristina Serrano; Falcón, María del Mar Serrano; Carmona, M. D. Ruiz; Solano, J. Linares; Ortega, Salvio Serrano

doi:10.1016/s0001-7310(06)73460-3

Cited by 6 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diseases such as psoriasis or psoriatic arthritis [51], lichen planus [50] and vitiligo also can present for the first time or be aggravated during interferon therapy. Pathophysiologically it is assumed that skin melanocytes are destroyed by the body's immune response towards the immunologic stimulus of the tumor cells due to antigen patterns similar to melanoma cells [53].…”

Section: Side Effects During Interferon Therapymentioning

confidence: 99%

Interdisciplinary management recommendations for toxicity associated with interferon‐alfa therapy

Hauschild

Kähler

Schäfer

et al. 2008

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Adjuvant interferon-alpha (IFN-alpha) therapy in patients with melanoma has been established as standard therapy since more than 10 years.During IFN-alpha therapy, flu-like symptoms, gastrointestinal disorders, arthralgias and neuropsychiatric symptoms are the most common side effects. The management and prophylaxis of these side effects have been improved by a more detailed understanding of pathophysiologic mechanisms and increased clinical experience. New insights in the relevance of detection of autoantibodies and development of autoimmunity have influenced the clinical pathway substantially. This review covers the pathomechanisms, incidence and optimized therapy of IFN-alpha-associated side effects.

show abstract

Section: Side Effects During Interferon Therapymentioning

confidence: 99%